Guobang Pharma Unit's DMG-PEG2000 Excipient Clears CDE Review, Registration Status Becomes A

On September 15, 2026, Guobang Pharma (605507) announced that the company recently learned from the Center for Drug Evaluation (CDE) of the National Medical Products Administration's "excipient and packaging material registration information" platform that the excipient "purified dimyristoyl glyceryl ester (for injection)" submitted by its wholly owned subsidiary Zhejiang Guobang Pharmaceutical Co. , Ltd. received an A result in the CDE joint review of excipients and formulations. The excipient's registration status has changed to A, meeting the supply conditions for downstream customers' commercial formulation production.

Purified dimyristoyl glyceryl ester (DMG-PEG2000) is a PEGylated lipid currently mainly used in the development and production of formulations in emerging fields such as mRNA vaccines, tumor therapeutic vaccines, protein replacement therapies and gene therapies, and is a key functional excipient for such formulations.